Gene,Category,IDH_Preference,Evidence_Level,Rationale,Target_Type,Druggability
CD74,Receptor,Both,SigXTalk+CellChat,MIF receptor; top specificity across all groups; MIF-CD74 axis in GBM immune evasion,mAb / ADC,High
CD44,Receptor,Both,SigXTalk+CellChat,SPP1/HA receptor; top specificity; linked to glioma invasion; TAM-targetable,mAb / CAR-T,High
CXCR4,Receptor,Both,CellChat+SigXTalk,MIF co-receptor; CXCR4-CXCL12 axis in GBM; FDA-approved plerixafor,Small molecule,Approved
CD99,Receptor,IDHmut,CellChat+SigXTalk+NicheNet,Immune checkpoint-like; IDHmut-specific high specificity; Ewing sarcoma target,mAb / ADC,Medium
FPR1,Receptor,Both,SigXTalk,Formyl peptide receptor; high specificity in TAMs; linked to chemotaxis,Small molecule,Medium
PTPRC,Receptor,Both,SigXTalk,CD45; pan-immune receptor; high specificity; well-established target,mAb / ADC,High
PLAUR,Receptor,Both,SigXTalk,uPAR; high specificity; linked to ECM degradation and invasion,Small molecule,Medium
TGFBR1,Receptor,IDHwt,CellChat+NicheNet,TGFB1 receptor; IDHwt-enriched signaling; galunisertib in glioma trials,Small molecule,Phase II
ITGA5,Receptor,IDHwt,CellChat,COLLAGEN receptor; focal adhesion; ECM signaling in IDHwt,mAb / Small mol,Medium
NCL,Receptor,Both,SigXTalk,Nucleolin; high specificity; multi-functional TAM receptor,mAb (APT-102),Medium
CCR5,Receptor,IDHwt,Inferred,CCL4/CCL5 receptor; TAM chemotaxis; maraviroc-approved,Small molecule,Approved
MIF,Ligand,Both,CellChat+NicheNet,Top pathway across groups; MIF-CD74 immune evasion; TAM-derived,Neutralizing Ab,Medium
SPP1,Ligand,IDHwt,CellChat+NicheNet,Osteopontin; IDHwt-enriched; TAM→Malignant; ECM remodeling,Neutralizing Ab,Medium
TGFB1,Ligand,IDHwt,NicheNet+CellChat,Active in IDHwt TAM receiver cells; immunosuppressive,Trap / mAb,Phase II
APP,Ligand,IDHmut,CellChat+NicheNet,IDHmut-specific top pathway; TAM-neuron signaling,BACE inhibitor,Medium
IL1B,Ligand,Both,ALL THREE METHODS,Cross-validated inflammatory axis; universal TAM-derived signal,Canakinumab (mAb),Approved
CCL4,Ligand,Both,ALL THREE METHODS,Cross-validated chemokine; CCR5/CCR1 signaling,Neutralizing Ab,Low
CXCL8,Ligand,IDHwt,ALL THREE METHODS,IL-8; cross-validated; neutrophil recruitment in IDHwt,Anti-IL8 mAb,Medium
TNF,Ligand,Both,CellChat+ML,ML top feature; inflammatory cytokine; infliximab-approved,Anti-TNF mAb,Approved
FN1,Ligand,IDHwt,CellChat+NicheNet,Fibronectin; ECM-derived; IDHwt enriched,Anti-FN1 Ab,Low
COL1A1,Ligand,IDHwt,CellChat,COLLAGEN 8.6x in IDHwt; ECM structural; TME remodeling,Anti-collagen Ab,Low
CEBPB,TF,IDHmut,SigXTalk only,Top IDHmut fidelity target; log2FC=4.0; master myeloid regulator,Small molecule,Low
HMOX1,Enzyme,IDHmut,SigXTalk only,IDHmut high fidelity; oxidative stress; NRF2 target,HMOX1 inhibitor,Medium
GPR84,GPCR,Both,ML top feature,Top ML feature (coef=+0.441); myeloid GPCR; GLPG1205 in trial,Small molecule,Phase II
IRAK2,Kinase,Both,ML top feature,TLR signaling; IRAK4 inhibitors in development,Kinase inhibitor,Phase I
ABL2,Kinase,Both,ML top feature,ABL family; imatinib target; -0.115 coefficient (IDHwt-protective),Kinase inhibitor,Approved
TNF,Cytokine,Both,CellChat+ML,Both ML top feature and CellChat pathway; dual-validated,Neutralizing Ab,Approved
IL1B,Cytokine,Both,ALL THREE METHODS,Cross-validated; inflammasome; canakinumab,Neutralizing Ab,Approved
